Get the Stockscreener App
14.84
3.38%
0.485
Delcath Systems Inc stock is traded at $14.84, with a volume of 940.90K.
It is up +3.38% in the last 24 hours and up +30.06% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$14.36
Open:
$14.37
24h Volume:
940.90K
Relative Volume:
2.23
Market Cap:
$414.56M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-5.2624
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+19.68%
1M Performance:
+30.06%
6M Performance:
+34.18%
1Y Performance:
+166.91%
1-Day Range:
$14.37
$15.98
1-Week Range:
$11.38
$15.98
52-Week Range:
$5.30
$16.97
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
14.84 | 414.56M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Delcath Systems First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DCTH Stock News - GuruFocus
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Delcath Systems, Inc. (NASDAQ:DCTH) Q1 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems (NASDAQ:DCTH) delivers shareholders stellar 45% CAGR over 3 years, surging 19% in the last week alone - simplywall.st
Delcath Systems Reports First Quarter 2025 Results and Business Highlights - BioSpace
Delcath Systems Inc (DCTH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Massive Stock Purchases Signal Confidence in Delcath Systems - TipRanks
Delcath Systems’ Earnings Call Highlights Growth and Challenges - TipRanks
Delcath Systems targets 30 active centers by year-end 2025 amid strong Q1 performance - MSN
Delcath Systems (DCTH) Reports Strong Q1 2025 Results, Eyes Expansion - GuruFocus
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings call transcript: Delcath Systems beats Q1 2025 forecasts, shares rise - Investing.com
Delcath (DCTH) Reports Strong Q1 Revenue Surpassing Expectations | DCTH Stock News - GuruFocus
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates - Yahoo Finance
Delcath Systems earnings beat, revenue topped estimates - Investing.com
Delcath Systems Inc (DCTH) Q1 2025 Earnings: EPS of $0.03 Beats Estimate, Revenue Surges to $19.8 Million - GuruFocus
Delcath Systems (DCTH) Surpasses Q1 Earnings and Revenue Expectations - GuruFocus
Delcath Systems Reports First Quarter 2025 Results and Business Highlights | DCTH Stock News - GuruFocus
Delcath Systems Reports Strong Q1 2025 Growth - TipRanks
Delcath Systems, Inc. (NASDAQ:DCTH) Shares Purchased by Barclays PLC - Defense World
(DCTH) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Repligen (RGEN) and CareDx (CDNA) - The Globe and Mail
FDA clears Delcath’s Phase 2 trial for breast cancer treatment By Investing.com - Investing.com South Africa
FDA clears Delcath’s Phase 2 trial for breast cancer treatment - Investing.com Australia
Delcath Systems Gets FDA Clearance to Start Phase 2 Trial of Hepzato for Metastatic Breast Cancer - marketscreener.com
Delcath Systems (DCTH) Cleared by FDA to Start Phase 2 Trial for Hepzato | DCTH Stock News - GuruFocus
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
FDA Green Lights Delcath's Breakthrough Liver Cancer Tech Expansion into Breast Cancer Market - Stock Titan
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer - The Joplin Globe
Geode Capital Management LLC Buys 37,056 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
Financial Metrics Unveiled: Delcath Systems Inc (DCTH)’s Key Ratios in the Spotlight - DWinneX
Delcath Systems Inc (DCTH) shows promising results - uspostnews.com
Liver Cancer Treatment Leader Delcath Systems to Report Q1 2025 Earnings May 8 - Stock Titan
(DCTH) Proactive Strategies - news.stocktradersdaily.com
Moffitt-Led International Study Finds New Drug Delivery System Effective Against Rare Eye Cancer - Central Florida Health News
Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock? - Nasdaq
Delcath Systems Announces Publication of Comparative Analysis fr - GuruFocus
Clinical Data: Delcath's Melanoma Treatment Achieves 175% Better Survival Than Standard Care - Stock Titan
How To Trade (DCTH) - news.stocktradersdaily.com
Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com
Hospitals Experience FOMO In Adopting Delcath’s PHP Treatment (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Is Expected To Breakeven In The Near Future - simplywall.st
Charles Schwab Investment Management Inc. Invests $156,000 in Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
5,470 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Acquired by Quantbot Technologies LP - Defense World
Delcath Systems (NASDAQ:DCTH) and West Pharmaceutical Services (NYSE:WST) Critical Survey - Defense World
Beta Bionics Announces Board Appointment of Gerard Michel - The Manila Times
Beta Bionics appoints new board member from Delcath Systems By Investing.com - Investing.com South Africa
Beta Bionics appoints new board member from Delcath Systems - Investing.com India
Jim Cramer Blesses Delcath Systems (DCTH): ‘You’re Not Early, But It’s a Win’ - MSN
Jim Cramer Discussed These 6 Stocks Recently - Insider Monkey
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):